A detailed history of Northern Trust Corp transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 95,350 shares of AMLX stock, worth $386,167. This represents 0.0% of its overall portfolio holdings.

Number of Shares
95,350
Previous 367,249 74.04%
Holding current value
$386,167
Previous $697,000 55.81%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$1.65 - $3.24 $448,633 - $880,952
-271,899 Reduced 74.04%
95,350 $308,000
Q2 2024

Aug 14, 2024

SELL
$1.62 - $2.71 $94,475 - $158,041
-58,318 Reduced 13.7%
367,249 $697,000
Q1 2024

May 14, 2024

SELL
$2.71 - $19.57 $26,747 - $193,155
-9,870 Reduced 2.27%
425,567 $1.21 Million
Q4 2023

Feb 13, 2024

BUY
$12.07 - $18.46 $116,584 - $178,305
9,659 Added 2.27%
435,437 $6.41 Million
Q3 2023

Nov 13, 2023

SELL
$18.08 - $23.45 $1.08 Million - $1.4 Million
-59,640 Reduced 12.29%
425,778 $7.8 Million
Q2 2023

Aug 11, 2023

BUY
$20.98 - $31.42 $451,867 - $676,723
21,538 Added 4.64%
485,418 $10.5 Million
Q1 2023

May 15, 2023

BUY
$27.71 - $40.93 $1.9 Million - $2.81 Million
68,741 Added 17.4%
463,880 $13.6 Million
Q4 2022

Feb 13, 2023

BUY
$29.75 - $39.26 $3.25 Million - $4.29 Million
109,331 Added 38.25%
395,139 $14.6 Million
Q3 2022

Nov 14, 2022

BUY
$17.15 - $30.92 $3.28 Million - $5.91 Million
191,267 Added 202.31%
285,808 $8.05 Million
Q2 2022

Aug 12, 2022

BUY
$6.85 - $19.93 $84,741 - $246,554
12,371 Added 15.06%
94,541 $1.82 Million
Q1 2022

May 13, 2022

BUY
$12.85 - $32.9 $1.06 Million - $2.7 Million
82,170 New
82,170 $1.06 Million

Others Institutions Holding AMLX

About Amylyx Pharmaceuticals, Inc.


  • Ticker AMLX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,533,200
  • Market Cap $237M
  • Description
  • Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...
More about AMLX
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.